Business Description
Insight Molecular Diagnostics Inc
NAICS : 541380
SIC : 8734
ISIN : US68235C1071
Total Employee Number:
58Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.19 | |||||
Equity-to-Asset | -0.26 | |||||
Debt-to-Equity | -0.29 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -15.58 | |||||
Beneish M-Score | -5.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.4 | |||||
3-Year EBITDA Growth Rate | 13.2 | |||||
3-Year EPS without NRI Growth Rate | 44.7 | |||||
3-Year FCF Growth Rate | 54.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 105.72 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.28 | |||||
9-Day RSI | 42.23 | |||||
14-Day RSI | 44.38 | |||||
3-1 Month Momentum % | 73.33 | |||||
6-1 Month Momentum % | -22 | |||||
12-1 Month Momentum % | 50 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.54 | |||||
Quick Ratio | 2.51 | |||||
Cash Ratio | 2.35 | |||||
Days Inventory | 188.54 | |||||
Days Sales Outstanding | 209.56 | |||||
Days Payable | 674.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -69.1 | |||||
Shareholder Yield % | -17.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.31 | |||||
Operating Margin % | -1791.79 | |||||
Net Margin % | -2454.64 | |||||
EBITDA Margin % | -2329.45 | |||||
FCF Margin % | -1413.28 | |||||
OCF Margin % | -1234.39 | |||||
ROA % | -108.24 | |||||
ROIC % | -153.76 | |||||
3-Year ROIIC % | 2.6 | |||||
ROC (Joel Greenblatt) % | -620.36 | |||||
ROCE % | -138.03 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 75.57 | |||||
EV-to-EBIT | -2.59 | |||||
EV-to-EBITDA | -2.73 | |||||
EV-to-Revenue | 63.48 | |||||
EV-to-Forward-Revenue | 9.93 | |||||
EV-to-FCF | -4.5 | |||||
Price-to-GF-Value | 3.68 | |||||
Earnings Yield (Greenblatt) % | -38.61 | |||||
FCF Yield % | -18.46 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Insight Molecular Diagnostics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.672 | ||
| EPS (TTM) (€) | -1.269 | ||
| Beta | 1.4883 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.66 | ||
| Volatility % | 94.15 | ||
| 14-Day RSI | 44.38 | ||
| 14-Day ATR (€) | 0.241493 | ||
| 20-Day SMA (€) | 4.6145 | ||
| 12-1 Month Momentum % | 50 | ||
| 52-Week Range (€) | 2.48 - 7.35 | ||
| Shares Outstanding (Mil) | 32.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Insight Molecular Diagnostics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Insight Molecular Diagnostics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 17:00 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 17:00 | In 29 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 28 days | ||
| General meeting for 2026 | 2026-06-11 12:00 | 4.90 (-0.41%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 14:00 | 4.18 (+2.96%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 4.18 (+2.96%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-15 09:30 | 2.50 (+0.81%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 17:00 | 3.46 (+3.59%) | ||
| Annual report for 2025 | 2026-03-26 | 3.46 (+3.59%) |
Show
Entries
Insight Molecular Diagnostics Inc Frequently Asked Questions
What is Insight Molecular Diagnostics Inc(FRA:7OC0)'s stock price today?
The current price of FRA:7OC0 is €4.30. The 52 week high of FRA:7OC0 is €7.35 and 52 week low is €2.48.
When is next earnings date of Insight Molecular Diagnostics Inc(FRA:7OC0)?
The next earnings date of Insight Molecular Diagnostics Inc(FRA:7OC0) is 2026-08-11 Est..
Does Insight Molecular Diagnostics Inc(FRA:7OC0) pay dividends? If so, how much?
Insight Molecular Diagnostics Inc(FRA:7OC0) does not pay dividend.
Press Release
Articles on Insight Molecular Diagnostics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers